Journal of clinical medicine
Cure8 research brief
Why This Matters
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic options for multi-system disease, but it is a single case and not proof of general benefit.
Who Should Pay Attention
Adult patients with ulcerative colitis (especially with PSC or other autoimmune disease), gastroenterologists, hepatologists
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a published case report describing a 32-year-old man with severe ulcerative colitis (UC) who also had primary sclerosing cholangitis (PSC) and systemic lupus erythematosus (SLE).
Initial UC treatments (mesalazine and immunosuppressants including azathioprine and cyclosporine) produced limited benefit; vedolizumab was started and the authors report marked clinical improvement and near-complete endoscopic remission of UC.
PSC and SLE were managed separately and remained clinically stable; the patient is awaiting liver transplantation for PSC. The article is an abstract/full-text case report in Journal of Clinical Medicine and summarizes a single-patient experience rather than a controlled study.
It illustrates that vedolizumab was used successfully in this complex clinical scenario but does not establish effectiveness or safety more broadly. If you have UC with other autoimmune conditions or PSC, treatment decisions should be individualized with your gastroenterologist and other specialists.
This report may be of interest when discussing biologic options in complex multi-system disease, but it is not evidence that vedolizumab will work the same way for others.
Keep In Mind
Single-patient case report from Journal of Clinical Medicine; anecdotal evidence only. Concurrent infections and other ongoing treatments limit generalizability.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of clinical medicine
AuthorsFu ST, Chang KP, Hong WJ +2 more
Study typeJournal article, case reports
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 2, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Vedolizumab for De Novo Ulcerative Colitis After Kidney Transplantation in a Patient With IgA Nephropathy: A Case Report.
People with IBD who’ve had organ transplants (or are concerned about infection risk from systemic immunosuppression) may be interested because vedolizumab’s gut‑selective action could be preferable after kidney...
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...